Paper

Preclinical safety and immunogenicity of Streptococcus pyogenes (Strep A) peptide vaccines

Published Jan 8, 2021 · Ainslie Calcutt, Victoria Ozberk, M. Good

Scientific Reports

Citations

Influential Citations

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Rigorous Journal

Study Snapshot

The two candidate Strep A peptide vaccines show no clinical toxicity and robust immunological response in rats, suggesting their safety for phase 1 clinical trials in healthy humans.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Preclinical safety and immunogenicity of Streptococcus pyogenes (Strep A) peptide vaccines

References

Citations